Pharmaceutical company Impax Laboratories Inc (NASDAQ:IPXL) reported on Tuesday the availability of the authorised generic version of Solodyn (minocycline HCl) extended-release tablets in 65 mg and 115 mg.
For the 12 months ending December 2017, Minocycline HCl extended-release tablets, 65 mg and 115 mg, had annual US sales of about USD148m according to IQVIA,
SOLODYN is indicated to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 12 years of age and older, added the company.
Impax is a specialty pharmaceutical company that markets its generic products through its Impax Generics division and its branded products through the Impax Specialty Pharma division.
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval
Newbury Pharmaceuticals secures first Scandinavian approval for palbociclib generic
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval
DifGen and Apotex report FDA approval of generic Nintedanib Soft Gel Capsules